Translations:Biosimilar/34/en
Jump to navigation
Jump to search
| Date of Biosimilar FDA Approval | Biosimilar Product | Original Product |
|---|---|---|
| March 2015 | filgrastim-sndz/Zarxio | filgrastim/Neupogen |
| April 2016 | infliximab-dyyb/Inflectra | infliximab/Remicade |
| August 2016 | etanercept-szzs/Erelzi | etanercept/Enbrel |
| September 2016 | adalimumab-atto/Amjevita | adalimumab/Humira |
| April 2017 | infliximab-abda/Renflexis | infliximab/Remicade |
| August 2017 | adalimumab-adbm/Cyltezo | adalimumab/Humira |
| September 2017 | bevacizumab-awwb/Mvasi | bevacizumab/Avastin |
| December 2017 | trastuzumab-dkst/Ogivri | trastuzumab/Herceptin |
| December 2017 | infliximab-qbtx/Ixifi | infliximab/Remicade |
| May 2018 | epoetin alfa-epbx/Retacrit | epoetin alfa/Procrit |
| June 2018 | pegfilgrastim-jmdb/Fulphila | pegfilgrastim/Neulasta |
| July 2018 | filgrastim-aafi/Nivestym | filgrastim/Neupogen |
| October 2018 | adalimumab-adaz/Hyrimoz | adalimumab/Humira |
| November 2018 | pegfilgrastim-cbqv/Udenyca | pegfilgrastim/Neulasta |
| November 2018 | rituximab-abbs/Truxima | rituximab/Rituxan |
| December 2018 | trastuzumab-pkrb/Herzuma | trastuzumab/Herceptin |
| January 2019 | trastuzumab-dttb/Ontruzant | trastuzumab/Herceptin |
| March 2019 | trastuzumab-qyyp/Trazimera | trastuzumab/Herceptin |
| April 2019 | etanercept-ykro/Eticovo | etanercept/Enbrel |
| June 2019 | trastuzumab-anns/Kanjinti | trastuzumab/Herceptin |
| June 2019 | bevacizumab-bvzr/Zirabev | bevacizumab/Avastin |
| July 2019 | rituximab-pvvr/Ruxience | rituximab/Rituxan |
| July 2019 | adalimumab-bwwd/Hadlima | adalimumab/Humira |
| November 2019 | pegfilgrastim-bmez/Ziextenzo | pegfilgrastim/Neulasta |
| November 2019 | adalimumab-afzb/Abrilada | adalimumab/Humira |
| December 2019 | infliximab-axxq/Avsola | infliximab/Remicade |
| June 2020 | pegfilgrastim-apgf/Nyvepria | pegfilgrastim/Neulasta |
| July 2020 | adalimumab-fkjp/Hulio | adalimumab/Humira |
| December 2020 | rituximab-arrx/Riabni | rituximab/Rituxan |
| July 2021 | insulin glargine-yfgn/Semglee | insulin glargine/Lantus |
| September 2021 | ranibizumab-nuna/Byooviz | ranibizumab/Lucentis |
| December 2021 | insulin glargine-aglr/Rezvoglar | insulin glargine/Lantus |
| December 2021 | adalimumab-aqvh/Yusimry | adalimumab/Humira |
| February 2022 | filgrastim-ayow/Releuko | filgrastim/Neupogen |
| April 2022 | bevacizumab-maly/Alymsys | bevacizumab/Avastin |
| May 2022 | pegfilgrastim-pbbk/Fylnetra | pegfilgrastim/Neulasta |
| August 2022 | ranibizumab-eqrn/Cimerli | ranibizumab/Lucentis |
| September 2022 | pegfilgrastim-fpgk/Stimufend | pegfilgrastim/Neulasta |
| September 2022 | bevacizumab-adcd/Vegzelma | bevacizumab/Avastin |
| December 2022 | adalimumab-aacf/Idacio | adalimumab/Humira |
| May 2023 | adalimumab-aaty/Yuflyma | adalimumab/Humira |
| August 2023 | natalizumab-sztn/Tyruko | natalizumab/Tysabri |
| September 2023 | tocilizumab-bavi/Tofidence | tocilizumab/Actemra |
| October 2023 | ustekinumab-auub/Wezlana | ustekinumab/Stelara |
| December 2023 | bevacizumab-tnjn/Avzivi | bevacizumab/Avastin |
| February 2024 | adalimumab-ryvk/Simlandi | adalimumab/Humira |
| March 2024 | denosumab-bbdz/Jubbonti | denosumab/Prolia |
| March 2024 | denosumab-bbdz/Wyost | denosumab/Xgeva |